Litcius/Paper detail

Atractylenolide III ameliorates spinal cord injury in rats by modulating microglial/macrophage polarization

Mengtong Xue, Wen‐Jie Sheng, Xue Song, Yujiao Shi, Zhijun Geng, Lin Shen, Rui Wang, He‐Zuo Lü, Jianguo Hu

2022CNS Neuroscience & Therapeutics81 citationsDOIOpen Access PDF

Abstract

BACKGROUND: Inflammatory reactions induced by spinal cord injury (SCI) are essential for recovery after SCI. Atractylenolide III (ATL-III) is a natural monomeric herbal bioactive compound that is mainly derived in Atractylodes macrocephala Koidz and has anti-inflammatory and neuroprotective effects. OBJECTIVE: Here, we speculated that ATL-III may ameliorate SCI by modulating microglial/macrophage polarization. In the present research, we focused on investigating the role of ATL-III on SCI in rats and explored the potential mechanism. METHODS: The protective and anti-inflammatory effects of ATL-III on neuronal cells were examined in a rat SCI model and lipopolysaccharide (LPS)-stimulated BV2 microglial line. The spinal cord lesion area, myelin integrity, and surviving neurons were assessed by specific staining. Locomotor function was evaluated by the Basso, Beattie, and Bresnahan (BBB) scale, grid walk test, and footprint test. The activation and polarization of microglia/macrophages were assessed by immunohistofluorescence and flow cytometry. The expression of corresponding inflammatory factors from M1/M2 and the activation of relevant signaling pathways were assessed by Western blotting. RESULTS: ATL-III effectively improved histological and functional recovery in SCI rats. Furthermore, ATL-III promoted the transformation of M1 into M2 and attenuated the activation of microglia/macrophages, further suppressing the expression of corresponding inflammatory mediators. This effect may be partly mediated by inhibition of neuroinflammation through the NF-κB, JNK MAPK, p38 MAPK, and Akt pathways. CONCLUSION: This study reveals a novel effect of ATL-III in the regulation of microglial/macrophage polarization and provides initial evidence that ATL-III has potential therapeutic benefits in SCI rats.

Topics & Concepts

NeuroinflammationMicrogliaNeuroprotectionSpinal cord injuryAstrogliosisMAPK/ERK pathwayp38 mitogen-activated protein kinasesChemistryPharmacologyProtein kinase BSpinal cordNeuroscienceSignal transductionInflammationCell biologyMedicineImmunologyBiologyCentral nervous systemSpinal Cord Injury ResearchNeuroinflammation and Neurodegeneration MechanismsImmune cells in cancer